Trial Profile
SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary)
- Indications Cardiovascular disorders; Myocardial infarction; Obesity; Stroke
- Focus Registrational; Therapeutic Use
- Acronyms SELECT
- Sponsors Novo Nordisk
- 08 Mar 2024 According to a Novo Nordisk media release, Dr. A. Michael Lincoff, Professor of Medicine at Cleveland Clinic and the lead study author of the SELECT outcomes trial.
- 08 Mar 2024 According to a Novo Nordisk media release, Novo Nordisk has also filed for a label expansion in the EU, and a decision is expected in 2024.
- 08 Mar 2024 According to a Novo Nordisk media release, company announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD).